Ipsen is a global specialty driven pharmaceutical company with total sales exceeding . billion in . Ipsen s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology, endocrinology and uro oncology. Moreover, the Group has an active policy of partnerships. R amp D is focused on innovative and differentiated technological patient driven platforms, peptides and toxins. In , R amp D expenditure totaled close to million, representing more than of Group sales. The Group has total worldwide staff of close to , employees.
Quote | Ipsen SA ADR (OTCMKTS:IPSEY)
Last: | $30.54 |
---|---|
Change Percent: | -2.52% |
Open: | $30.54 |
Close: | $30.54 |
High: | $30.54 |
Low: | $30.54 |
Volume: | 242 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Ipsen SA ADR (OTCMKTS:IPSEY)
2024-04-24 02:26:32 ET More on Ipsen S.A. Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases Ipsen secures exclusive global rights of Sutro Biopharma's STR...
2024-04-22 02:47:42 ET More on Ipsen S.A. Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADC Ipsen gets FDA approval for pancreatic cancer drug regimen Hist...
Message Board Posts | Ipsen SA ADR (OTCMKTS:IPSEY)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $IPSEY News Article - Onivyde Regimen Demonstrated Statistically Significant Improvemen | whytestocks | investorshangout | 11/09/2022 6:50:50 PM |
whytestocks: $IPSEY News Article - Ipsen and Marengo Therapeutics Announce Strategic Partnership to | whytestocks | investorshangout | 08/01/2022 4:35:54 PM |
Emylers: IPSEY Financials 07/16/2014 09:26:03 Ipsen S.A. Period Ending Total Revenue Cost of Revenue | Emylers | investorshangout | 07/16/2014 2:26:00 PM |
Stock_Tracker: Latest Ipsen S.A. ADR (IPSEY) Headlines Ipsen's net profit up by 6.4% in H1 2013 | Stock_Tracker | investorshangout | 03/10/2014 10:58:33 AM |
chartguy89: IPSEY 11.41 Stock Charts $IPSEY 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 4:47:14 AM |
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...